Seeking Alpha

Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite SUPN)...

Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite receiving approval from the FDA for its epilepsy treatment, Oxtellar XR, a once-daily extended release formulation of oxcarbazepine. The FDA also granted a waiver for the pediatric study requirement for ages birth to one month and a deferral for submission of post-marketing assessments for children one month to 6 years of age.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|